We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Javelin Pharmaceuticals | AMEX:JAV | AMEX | Ordinary Share |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.00 | - |
From Jan 2020 to Jan 2025
News release service Business Wire has reported a fake press release involving Javelin Pharmaceuticals Inc. (JAV) that ran on its service Friday night to the Federal Bureau of Investigation, Business Wire Chief Executive Cathy Tamraz said.
The FBI couldn't immediately be reached. Tamraz said her firm has reported the case to the New York bureau of the FBI, and the case is being treated as a "criminal investigation."
Javelin Pharmaceuticals Monday morning announced that on June 18 Business Wire inadvertently issued a hoax press release titled "US Supreme Court split -- rules in favor of Big Pharma" that falsely identified Javelin Pharmaceuticals as the issuer of the information. The information in the hoax release was false, Javelin's statement said. Business Wire received the hoax release from an unknown third party, purporting to be an authorized representative of the company, Javelin's Monday statement said.
-By Anjali Cordeiro, Dow Jones Newswires; 212-416-2200; anjali.cordeiro@dowjones.com
1 Year Javelin Pharmaceuticals Chart |
1 Month Javelin Pharmaceuticals Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
